The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease

Expert Opinion on Drug Safety

Volumn 3, Issue 5, 2004, Pages 425-440

  Thompson, Sarah ^b   Lanctôt, Krista L ^a   Hermann, Nathan ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

Acetylcholine (ACh); Adverse events (AEs); Alzheimer's disease (AD); Cholinesterase inhibitors (ChEIs); Dementia; Donepezil; Drug interactions; Galantamine; Rivastigmine; Safety; Switching; Tolerability

Indexed keywords

ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ATRACURIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PAROXETINE; RISPERIDONE; RIVASTIGMINE; SUXAMETHONIUM; TIAPRIDE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APATHY; BRADYCARDIA; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ESOPHAGUS RUPTURE; EXTRAPYRAMIDAL SYMPTOM; FALLING; HALLUCINATION; HEADACHE; HUMAN; MAXIMUM PERMISSIBLE DOSE; MYALGIA; NAUSEA; PANIC; PARKINSONISM; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

AGED; ALZHEIMER DISEASE; ANIMALS; BASAL GANGLIA DISEASES; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG INTERACTIONS; FEMALE; GALANTAMINE; GASTROINTESTINAL DISEASES; HUMANS; INDANS; INSTITUTIONALIZATION; LONGITUDINAL STUDIES; MALE; MEMANTINE; META-ANALYSIS; MICE; MIDDLE AGED; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; SINGLE-BLIND METHOD; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 4544248755     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.5.425     Document Type: Review

References (130)

1. CANADIAN STUDY OF HEALTH AND AGING WORK GROUP: Canadian study of health and aging: study methods and prevalence of dementia. CMAJ (1994) 150(6):899-913.
2. FRATIGLIONI L, LAUNER LJ, ANDERSEN K et al.: Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 54(11 Suppl. 5):S10-S15.
3. HEBERT LE, SCHERR PA, BIENIAS JL, BENNETT DA, EVANS DA: Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. (2003) 60(8):1119-1122.
4. KATZMAN R: Alzheimer's disease. N. Engl. J. Med. (1986) 314(15):964-973.
5. DRACHMAN DA: Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology (1977) 27(8):783-790.
6. PERRY EK: The cholinergic system in old age and Alzheimer's disease. Age Ageing (1980) 9(1):1-8.
7. BOADA-ROVIRA M, BRODATY H, CRAS P et al.: Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging (2004) 21(1):43-53.
8. CLEGG A, BRYANT J, NICHOLSON T et al.: Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol. Assess. (2001) 5(1):1-137.
9. SMALL GW, RABINS PV, BARRY PP et al.: Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA (1997) 278(16):1363-1371.
10. DOODY RS, STEVENS JC, BECK C et al.: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 56(9):1154-1166.
11. WINBLAD B, ENGEDAL K, SOININEN H et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 57(3):489-495.
12. MOHS RC, DOODY RS, MORRIS JC et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 57(3):481-488.
13. ROGERS S, WALTERS EJ, FRIEDHOFF LT: The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 (R,S)-1benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl)-methylpiperidine hydrochloride) a novel inhibitor of acetylcholinesterase (AChE): implications for use in the treatment of Alzheimer's disease. Neurobiol. Aging (1992) 13:496.
14. MIHARA M, OHNISHI A, TOMONO Y et al.: Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31(5):223-229.
15. BARNER EL, GRAY SL: Donepezil use in Alzheimer's disease. Ann. Pharmacother. (1998) 32(1):70-77.
16. TISEO PJ, PERDOMO CA, FRIEDHOFF LT: Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):25-29.
17. TISEO PJ, PERDOMO CA, FRIEDHOFF LT: Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):30-34.
18. TISEO PJ, FOLEY K, FRIEDHOFF LT: Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):35-39.
19. TISEO PJ, PERDOMO CA, FRIEDHOFF LT: Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):40-44.
20. TISEO PJ, FOLEY K, FRIEDHOFF LT: The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):45-50.
21. BRYSON HM, BENFIELD P: Donepezil. Drugs Aging (1997) 10(3):234-239; discussion 240-231.
22. ENZ A, AMSTUTZ R, BODDEKE H, GMELIN G, MALANOWSKI J: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. (1993) 98:431-438.
23. WRIGHT CI, GEULA C, MESULAM MM: Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann. Neurol. (1993) 34(3):373-384.
24. WRIGHT CI, GEULA C, MESULAM MM: Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Ann. N Y Acad. Sci. (1993) 695:65-68.
25. WEINSTOCK M: Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs (1999) 12:307-323.
26. PERRY EK, TOMLINSON BE, BLESSED G et al.: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. (1978) 2(6150):1457-1459.
27. DARVESH S, HOPKINS DA, GEULA C: Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. (2003) 4(2):131-138.
28. RÖSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. (1999) 318(7184):633-638.
29. COREY-BLOOM J, ANAND R, VEACH J, THE ENA 713 B352 STUDY GROUP: A randomized trial evaluating the efficacy and saftey of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriat. Psychopharmacol. (1998) 1:55-65.
30. SPENCER CM, NOBLE S: Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging (1998) 13(5):391-411.
31. ANAND R, GHARABAWI G, ENZ A: Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J. Drug Dev. Clin. Pract. (1996) 8:1-14.
32. POLINSKY RJ: Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. (1998) 20(4):634-647.
33. Product Monograph. In: Compendium of Pharmaceuticals and Specialities: The Canadian Drug Reference for Health Professionals (2003):739.
34. INGLIS F: The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. (2002) 127:45-63.
35. COYLE J, KERSHAW P: Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry (2001) 49(3):289-299.
36. SCOTT LJ, GOA KL: Galantamine: a review of its use in Alzheimer's disease. Drugs (2000) 60(5):1095-1122.
37. SRAMEK JJ, FRACKIEWICZ EJ, CUTLER NR: Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin. Investig. Drugs (2000) 9(10):2393-2402.
38. LOPEZ-ARRIETA JM, RODRIGUEZ JL, SANZ F: Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst. Rev. (2001) (2):CD001749.
39. REZVANI AH, LEVIN ED: Cognitive effects of nicotine. Biol. Psychiatry (2001) 49(3):258-267.
40. KEWITZ H: Pharmacokinetics and metabolism of galanthamine. Drugs Today (1997) 33:265-272.
41. RAINER M: Clinical studies of galanthamine. Drugs Today (1997) 4:273-279.
42. WILCOCK GK, LILIENFELD S, GAENS E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br. Med. J. (2000) 321(7274):1445-1449.
43. FRANCIS PT, PALMER AM, SNAPE M, WILCOCK GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry (1999) 66(2):137-147.
44. KRALL WJ, SRAMEK JJ, CUTLER NR: Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease. Ann. Pharmacother. (1999) 33(4):441-450.
45. MAYEUX R, SANO M: Treatment of Alzheimer's disease. N. Engl. J. Med. (1999) 341(22):1670-1679.
46. THAL LJ: Cholinomimetic treatment of Alzheimer's disease. Prog. Brain Res. (1996) 109:299-309.
47. WINBLAD B, BRODATY H, GAUTHIER S et al.: Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int. J. Geriatr. Psychiatry (2001 16(7):653-666.
48. LANCTOT KL, HERRMANN N, YAU KK et al.: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ (2003) 169(6):557-564.
49. TRINH NH, HOBLYN J, MOHANTY S, YAFFE K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA (2003) 289(2):210-216.
50. TARIOT PN, SOLOMON PR, MORRIS JC et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 54(12):2269-2276.
51. ROCKWOOD K, MINTZER J, TRUYEN L, WESSEL T, WILKINSON D: Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry (2001) 71(5):589-595.
52. ROGERS SL, FRIEDHOFF LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia (1996) 7(6):293-303.
53. AGID Y, DUBOIS B, THE INTERNATIONAL RIVASTIGMINE INVESTIGATORS, ANAND R, GHARABAWI G: Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr. Ther. Res. (1998) 59(12):837-845.
54. SCHNEIDER LS: Cholinesterase inhibitors for Alzheimer's disease. JAMA (2003) 289(18):2359-2360; author reply 2360-2351.
55. DAVIS KL, MOHS RC, MARIN D et al.: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA (1999) 281(15):1401-1406.
56. GAUTHIER S, FELDMAN H, HECKER J et al.: Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr. Med. Res. Opin. (2002) 18(6):347-354.
57. GAUTHIER S, FELDMAN H, HECKER J et al.: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. (2002) 14(4):389-404.
58. FELDMAN H, GAUTHIER S, HECKER J et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 57(4):613-620.
59. FELDMAN H, GAUTHIER S, HECKER J et al.: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J. Am. Geriatr. Soc. (2003) 51(6):737-744.
60. BURNS A, SPIEGEL R, QUARG P: Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int. J. Geriatr. Pychiatry (2004) 19(3):243-249.
61. WILKINSON DG, PASSMORE AP, BULLOCK R et al.: A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. (2002) 56(6):441-446.
62. WILCOCK G, HOWE I, COLES H et al.: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging (2003) 20(10):777-789.
63. GOLDLIST B, GORDON M, NAGLIE G: Galantamine versus donepezil in the treatment of Alzheimer's disease. Drugs Aging (2003) 20(15):1139-1140; author reply 1140.
64. JONES RW, SOININEN H, HAGER K et al.: A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int. J. Geriatr. Psychiatry (2004) 19(1)58-67.
65. KAWAS CH, CLARK CM, FARLOW MR et al.: Clinical trials in Alzheimer's disease: debate on the use of placebo controls. Alzheimer Dis. Assoc. Disord. (1999) 13(3):124-129.
66. RASKIND MA, PESKIND ER, TRUYEN L, KERSHAW P, DAMARAJU CV: The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol. (2004) 61(2):252-256.
67. MARCUSSON J, BULLOCK R, GAUTHIER S, KURZ A, SCHWALEN S: Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer's disease. Alzheimer Dis. Assoc. Disord. (2003) 17(Suppl. 3):S86-S91.
68. BLESA R, DAVIDSON M, KURZ A et al.: Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement. Geriatr. Cogn. Disord. (2003) 15(2):79-87.
69. DORAISWAMY PM, KRISHNAN KR, ANAND R et al.: Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(4):705-712.
70. DOODY RS, GELDMACHER DS, GORDON B, PERDOMO CA, PRATT RD: Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch. Neurol. (2001) 58(3):427-433.
71. DOODY RS, DUNN JK, CLARK CM et al.: Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2001) 12(4):295-300.
72. GELDMACHER DS, PROVENZANO G, MCRAE T, MASTEY V, IENI JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. (2003) 51(7):937-944.
73. LOPEZ OL, BECKER JT, WISNIEWSKI S et al.: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (2002) 72(3):310-314.
74. FINUCANE TE: Another advertisement for donepezil. J. Am. Geriatr. Soc. (2004) 52(5):843; author reply 845-846.
75. ROYALL DR: Donepezil's effects remain uncertain. J. Am. Geriatr. Soc. (2004) 52(5):843-844; author reply 845-846.
76. KARLAWISH JH: Donepezil delay to nursing home placement study is flawed. J. Am. Geriatr. Soc. (2004) 52(5):845; author reply 845-846.
77. SCHNEIDER LS, QIZILBASH N: Delay in nursing home placement with donepezil. J. Am. Geriatr. Soc. (2004) 52(6):1024-1026.
78. MASSOULIE J, PEZZEMENTI L, BON S, KREJCI E, VALLETTE FM: Molecular and cellular biology of cholinesterases. Prog. Neurobiol. (1993) 41(1):31-91.
79. ATACK JR, PERRY EK, BONHAM JR, CANDY JM, PERRY RH: Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J. Neurochem. (1986) 47(1):263-277.
80. BABIC T, BANFIC L, PAPA J et al.: Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. Age Ageing (2000) 29(4):370-371.
81. KUMAR V: Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. Age Ageing (2001) 30(2):177.
82. BORDIER P, GARRIGUE S, BAROLD SS et al.: Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace (2003) 5(4):429-431.
83. WALSH E, DOURISH J: Prolonged QT interval with rivastigmine. Br. J. Psychiatry (2002) 180:466.
84. INGLIS F: Rivastigmine and QT interval prolongation. Br. J. Psychiatry (2003) 182:549-550; author reply 550-541.
85. TARIOT PN, CUMMINGS JL, KATZ IR et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J. Am. Geriatr. Soc. (2001) 49(12):1590-1599.
86. BOUMAN WP, PINNER G: Violent behavior associated with donepezil. Am. J. Psychiatry (1998) 155(11):1626-1627.
87. DUNN NR, PEARCE GL, SHAKIR SA: Adverse effects associated with the use of donepezil in general practice in England. J. Psychopharmacol. (2000) 14(4):406-408.
88. ARAI M: Parkinsonism onset in a patient concurrently using tiapride and donepezil. Intern. Med. (2000) 39(10):863.
89. MAGNUSON TM, KELLER BK, BURKE WJ: Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am. J. Psychiatry (1998) 155(10):1458-1459.
90. MIYAOKA T, SENO H, YAMAMORI C et al.: Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J. Clin. Psychiatry (2001) 62(7):573-574.
91. MATSUMOTO T, KAWANISHI C, ISOJIMA D et al.: Neuroleptic malignant syndrome induced by donepezil. Int. J. Neuropsychopharmacol. (2004) 7(1):101-103.
92. LITVAN I, PHIPPS M, PHARR VL et al.: Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology (2001) 57(3):467-473.
93. MCKEITH I, DEL SER T, SPANO P et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 356(9247):2031-2036.
94. LEROI I, BRANDT J, REICH SG et al.: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry (2004) 19(1):1-8.
95. AARSLAND D, LAAKE K, LARSEN JP, JANVIN C: Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Pychiatry (2002) 72(6):708-712.
96. SCHREDL M, WEBER B, LEINS ML, HEUSER I: Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp. Gerontol. (2001) 36(2):353-361.
97. ROSS JS, SHUA-HAIM JR: Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J. Am. Geriatr. Soc. (1998) 46(1):119-120.
98. RIEMANN D, GANN H, DRESSING H, MULLER WE, ALDENHOFF JB: Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res. (1994) 51(3):253-267.
99. STAHL SM, MARKOWITZ JS, PAPADOPOULOS G, SADIK K: Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr. Med. Res. Opin. (2004) 20(4):517-524.
100. ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 50(1):136-145.
101. HASHIMOTO M, IMAMURA T, TANIMUKAI S, KAZUI H, MORI E: Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet (2000) 356(9229):568.
102. CARRIER G, BRUNET RC: A toxicokinetic model to assess the risk of azinphosmethyl exposure in humans through measures of urinary elimination of alkylphosphates. Toxicol. Sci. (1999) 47(1):23-32.
103. WEISER M, ROTMENSCH HH, KORCZYN AD et al.: A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int. J. Geriatr. Psychiatry (2002) 17(4):343-346.
104. GROSSBERG GT, STAHELIN HB, MESSINA JC, ANAND R, VEACH J: Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int. J. Geriatr. Psychiatry (2000) 15(3):242-247.
105. GAUTHIER S: Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging (2001) 18(11):853-862.
106. SANCHEZ MORILLO J, DEMARTINI FERRARI A, ROCA DE TOGORES LOPEZ A: Interaction of donepezil and muscular blockers in Alzheimer's disease. Rev. Esp. Anestesiol. Reanim. (2003) 50(2):97-100.
107. HEATH ML: Donepezil and succinylcholine. Anaesthesia (2003) 58(2):202.
108. EMRE M: Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int. J. Clin. Pract. Suppl. (2002) 127:64-72.
109. MORRIS JC: Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction. Clin. Ther. (2001) 23(Suppl. A):A1-A2.
110. GAUTHIER S, EMRE M, FARLOW MR et al.: Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr. Med. Res. Opin. (2003) 19(8):707-714.
111. EDWARDS KR, GOODMAN W, KHOURY KN: Rapid changeover from donepezil to rivastigmine well tolerated. J. Am. Geriatr. Soc. (2001) 49:S91-S92.
112. AURIACOMBE S, PERE JJ, LORIA-KANZA Y, VELLAS B: Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr. Med. Res. Opin. (2002) 18(3):129-138.
113. MCRAE TD, SCHWAM EM: Comments on efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr. Med. Res. Opin. (2002) 18(6):i-iii; author reply iv-vi.
114. RASMUSEN L, YAN B, ROBILLARD A, DUNBAR F: Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin. Ther. (2001) 23(Suppl. A):A25-A30.
115. MEEK PD, MCKEITHAN K, SCHUMOCK GT: Economic considerations in Alzheimer's disease. Pharmacotherapy (1998) 18(2 Pt 2):68-73; discussion 79-82.
116. O'BRIEN BJ, GOEREE R, HUX M et al.: Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J. Am. Geriatr. Soc. (1999) 47(5):570-578.
117. WIMO A, WINBLAD B, ENGEDAL K et al.: An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord. (2003) 15(1):44-54.
118. CARO J, GETSIOS D, MIGLIACCIO-WALLE K, ISHAK J, EL-HADI W: Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis. BMC Geriatr. (2003) 3(1):6.
119. KAUFER D, FRIEDMAN A, SEIDMAN S, SOREQ H: Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature (1998) 393(6683):373-377.
120. DAVIDSSON P, BLENNOW K, ANDREASEN N et al.: Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci. Lett. (2001) 300(3):157-160.
121. NORDBERG A, DARREHH-SHORI T, SVENSSON AL: Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J. Neurol. Sci (2001) 187(Suppl. 1):P0144.
122. SINGH S, DUDLEY C: Discontinuation syndrome following donepezil cessation. Int. J. Geriatr. Psychiatry (2003) 18(4):282-284.
123. CASADEMONT J, MIRO O, RODRIGUEZ-SANTIAGO B et al.: Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. J. Neurol. Sci. (2003) 206(1):23-26.
124. SVENSSON AL, NORDBERG A: Tacrine and donepezil attenuate the neurotoxic effect of A beta(25 - 35) in rat PC12 cells. Neuroreport (1998) 9(7):1519-1522.
125. KRISHNAN KR, CHARLES HC, DORAISWAMY PM et al.: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry (2003) 160(11):2003-2011.
126. INESTROSA NC, ALVAREZ A, PEREZ CA et al.: Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron (1996) 16(4):881-891.
127. MESULAM MM, ASUNCION MORAN M: Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann. Neurol. (1987) 22(2):223-228.
128. TARIOT PN, FARLOW MR, GROSSBERG GT et al.: Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 291(3):317-324.
129. HARTMANN S, MOBIUS HJ: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. (2003) 18(2):81-85.
130. WENK GL, QUACK G, MOEBIUS HJ, DANYSZ W: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. (2000) 66(12):1079-1083.